Novacyt (LON:NCYT) Posts Earnings Results

Novacyt (LON:NCYT) posted its earnings results on Wednesday. The company reported GBX (8) earnings per share for the quarter, Digital Look Earnings reports. Novacyt had a negative net margin of 103.08% and a negative return on equity of 96.44%.

Novacyt Stock Down 0.9%

LON:NCYT traded down GBX 0.40 during mid-day trading on Wednesday, hitting GBX 42.50. The company had a trading volume of 48,827 shares, compared to its average volume of 175,000. The business has a fifty day simple moving average of GBX 41.77 and a 200-day simple moving average of GBX 39.06. The company has a current ratio of 4.74, a quick ratio of 4.46 and a debt-to-equity ratio of 44.74. Novacyt has a 1 year low of GBX 26.60 and a 1 year high of GBX 86. The firm has a market capitalization of £30.81 million, a price-to-earnings ratio of -1.33 and a beta of 1.11.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.